Here it is!! On clinicaltrials.gov!! YES and YAY. We are getting closer and closer to a cure for the most common cause of blindness in the developed world. There’s only one possible response to this… make a pumpkin pie! 🙂 (Oh, okay, I was already going to do that anyway…) But I’ll let you know how it turned out. For a truly excellent article explaining what this means, I’ll send you to the one and only Dr. Hartman’s (aka Deadally’s) analysis on Seeking Alpha:
Ocata Therapeutics Is An Official Phase 2 Biotech: AMD Efficacy Study Design Details
And here’s a comment I just left on the article:
Thanks so much for this excellent article, Dr. Hartman! 🙂 So many people could be helped this way. And as I know all too well… NOT everyone who has some form of MD is ninety years old. I’m certainly not, but it does get worse than that. Every time I’ve been at Casey Eye Institute, I’ve seen small children with Stargardt’s. It’s one of the saddest sights you could ever imagine. I know I’ll never forget the time I saw a baby with bandages over its face being wheeled down the hall in a huge cot enclosed by bars. What Ocata is doing will ultimately provide the opportunity to save people of all ages from blindness.
Here’s the press release.
(STARES at today’s news)
*^()&)*(&)*(&)*( I DON’T EVEN.
(RUNS around yelling incoherently, but happily.)
THIS… this is what we’ve been waiting for. Ocata is officially now going to start Phase 2 of the AMD study.
There’s so much to be said here… it’ll have to get done later on… but for now… HAPPY. Just plain… happy. 🙂
This is REALLY exciting… I had a few thoughts about it to share on Facebook, and I’m reposting them here:
Cures for autoimmune diseases ARE possible!! They’re on their way, and they could be almost here! Well, there’s just ONE problem… they originally came from a stem cell line where at SOME point, LONG long ago, a three day old blastocyst was destroyed. One that would otherwise have been thrown out at a fertility clinic. One that never had a chance of being an embryo. Fifty million people have autoimmune diseases in America alone. Are they more important than one blastocyst that was sacrificed years ago? There are people who say yes. We are headed for a showdown. Share if you are on the side of the fifty million!!
New Ocata Press Release About Autoimmune Treatments in the Pipeline!!
Here’s the link for the original South Korean article showing even more positive results for patients when the Ocata technique was used. This is a much smaller study with only four people, and I think the real value is that it supports the original results in the Lancet. There were two AMD and two SMD patients, and when I read the full article, I could see that all of them had improvements. Three were very significant (vision improved 50%, 100% (twice as good, and I can never remember if that should be 100% or 200%), and 1300% improvement– yes, vision that was thirteen times better than before the study!
The fourth person wasn’t considered to have significant improvement, but I’m not so sure that I would agree. Their vision went from being able to read one letter to two, and when your vision is that bad to start with, any improvement helps.
Anyway… I highly recommend reading the whole article. The complete pdf if available for free, which is usually not the case– so take advantage of it!
Treatment of Macular Degeneration Using Embryonic Stem Cell-Derived Retinal Pigment Epithelium: Preliminary Results in Asian Patients
Posted in Great News
Tagged amd, asian patients, CHA, cure, Hyun-Ju Kim, ISSCR, Jae Ho Lee, Jinjung Choi, Kyung-Mi Park, Lucian V. Del Priore, Macular Degeneration, ocata, robert lanza, SMD, So Young Chong, South Korea, stem cell reports, stem cells, Sung Han Shim, Won Kyung Song
YES! These are the results we’ve been waiting for from CHA in So. Korea. They are great, and they 100% support the Lancet results from Ocata’s own trials. The thing that really impresses me about the CHA results is that just like Ocata’s, they were published in a peer-reviewed journal instead of being released through a company announcement. I have to say, I’m kind of over company announcements. (Remember when StemCells Inc did that??) Anyone can announce anything. I can announce that I just won Powerball. That doesn’t make it true! An article in a peer-reviewed journal is the gold standard.
Anyway, here’s a snippet, although you really need to go the link:
Here’s a cogent, intelligent, and rational comment to the news below:
3458qu9fqu4589q3u-!!!!! OMG I DON’T EVEN. O.o.
This moment has been brought to you by the Department of Medical Miracles to Come. 🙂
THIS IS WHAT WE’VE BEEN WAITING FOR!!! It’s the OFFICIAL announcement! Ocata can now start the second trial! They have pivotal trial status from the European Medicines Agency! This means that they can start marketing the drug after the next trial is over! It would be the FIRST stem cell based drug approved since 1956! Yes, I really DO think that we need all of these exclamation points!!!
Capslock? What capslock? 😉
Ahem. Anyway, check it out. 🙂
Ocata’s Press Release on the Completion of Phase I/II of SMD Trials
If you haven’t seen this one already, you do NOT want to miss it!!
Stem cell treatment of degenerative eye disease.
A really great, broad overview of what’s going on with the usefulness of different types of stem cells and vision right now. It’s even BETTER if you have institutional access and can read the entire article… but either way, don’t miss this one.
So, I was posting a summary for my book on the NaNoWriMo Facebook page, thinking that it sounded over the top… stem cell-based cures for horrible incurable diseases within 2-10 years, that kind of thing… well….
There’s no link for this, because it is insider info from shareholders who went to Ocata’s quarterly meeting in Boston, which was not open to the public. (There is a LOT about Ocata in the book– they’re the biotech company that just changed their name from Advanced Cell Technology.) Ocata is the company developing the first cure (or even treatment!) for age-related macular degeneration, a disease that slowly causes blindness for 30 million people in the U.S. and Europe alone. The interim published results for the clinical trials have looked great, but as far as when this treatment might actually come to market… it’s everybody’s guess.
But in the quarterly meeting… several attendees have all said the same thing. The drug already has orphan treatment approval for a genetic disease caused Stargardt’s, which has exactly the same effects and eventually causes blindness. But it attacks much younger people, including children as young as six. (Yep, six years old.) AND… the CEO of Ocata said that the drug will be available in the U.K. in 2018. We don’t have absolute confirmation of this yet. But it’s apparently what was officially said at that meeting.
One of the lines of thought on the forums is that the date might be earlier for AMD approval in the U.S, even quite a bit earlier if the drug is fast tracked here… we just don’t know. But this is INCREDIBLE!!!~ There has never ever been any kind of treatment for Stargardt’s before, and now there will be, and it will be STEM CELL BASED. As of now, that will be the first drug approved anywhere in the WORLD that is embryonic stem cell based.
YES! IT’S THE START OF A NEW ERA IN MEDICINE!!! And it will be in the book!
(sorry about the capslock…
Posted in Great News
Tagged advanced cell technology, amd, cure for blindness, cures, embryonic stem cells, investigational drugs, miracles, ocata, robert lanza, stargardt, stargardt's, stem cell, stem cells, treatments, trials